Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors
US11191771B2 · kind B2 · utility
1Cited by
9References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 8, 2017 |
| Grant date | Dec 7, 2021 |
| Priority date | — |
| Expiry date | Sep 17, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/2866
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to treatment of cancer using a antibody drug conjugates that comprise PBD molecules in combination with FLT3 inhibitors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.